Exploring the effects of paclitaxel-loaded zein nanoparticles on human ovarian carcinoma cells.

The development of innovative antitumor formulations that are able to increase the mortality of cancer cells while decreasing the efficacious pharmacological dosage is a fundamental goal of modern oncological research. In this study a paclitaxel (PTX)-nanomedicine was tested on two lines of human high-grade serous ovarian carcinoma (hHGS-OC). Zein, a vegetal protein, was employed to obtain nanoparticles containing the lipophilic compound (NanoPTX) characterized by a mean diameter of 160 nm, a narrow size distribution, a negative zeta potential and a prolonged release of the drug over time. NanoPTX was tested on HEY and COV362 cells demonstrating an increase of apoptosis, particularly on the papillary cystadenocarcinoma cells (55.2% p value 0.037 for NanoPTX vs 70.25%, p value 0.08 for PTX) with respect to the free form of the drug. The fluorescent nanosystems were characterized by a significant cell uptake after a few hours of incubation and they promoted a reduction in the intracellular reactive oxygen species. The results need to be validated on different hHGS-OC cells and the real efficacy of the proposed nanomedicine needs to be investigated using in vivo models of ovarian carcinoma.